Sign inJoin waitlistJoin the waitlist

Roberto Leon-Ferre

Associate Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2012–2015
Infectious Disease
University of Iowa Health Care Medical Center
2010–2012
Internal Medicine
University of Iowa Hospitals and Clinics
2007–2010
Universidad Católica de Santiago de Guayaquil Facultad de Ciencias Médicas
2003–2007

Research

Advances in systemic therapies for triple negative breast cancer
Review · BMJ · 2023 · First of 2 authors · 478 citations
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Journal of Thrombosis and Haemostasis · 2020 · 435 citations
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
JAMA · 2024 · First of 34 authors · 197 citations

Matthew Goetz
24 papers
Judy Boughey
22 papers
James Ingle
14 papers
JC
Jodi Carter
13 papers
Karthik Giridhar
12 papers · 1 as a fellow
Kathryn Ruddy
12 papers
Siddhartha Yadav
8 papers
CL
Charles Loprinzi
7 papers
ML
Minetta Liu
7 papers
Robert Mutter
7 papers
Tina Hieken
7 papers
Tufia Haddad
5 papers

Grants

Preclinical and Clinical Characterization of DNMT Inhibitors +/- Standard Chemoimmunotherapy in TNBC
National Cancer Institute · R01
PI · $935.9K · Mayo Clinic Rochester
2024–2029

Clinical trials

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Principal investigator · Suspended · Phase 1
National Cancer Institute (NCI)
2023–2027
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
Principal investigator · Active not recruiting
Mayo Clinic
2021–2028
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033
PRE-ISPY Phase I/II Oncology Platform Program
Site PI · Recruiting · Phase 1, Phase 2
QuantumLeap Healthcare Collaborative
2023–2031